Lung Cancer Management最新文献

{"title":"Cost of managing brain metastases in patients with ALK+ advanced NSCLC with first-line tyrosine kinase inhibitors in the UK.","authors":"Hannah Le, Daniel Ladino, Chrissy Lowry, Nada Rifi, Shobhit Baijal","doi":"10.1080/17581966.2026.2696220","DOIUrl":"10.1080/17581966.2026.2696220","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to estimate the NHS costs of managing patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small-cell lung cancer (aNSCLC), with and without brain metastases. Patients were treated with first-line (1 L) ALK tyrosine kinase inhibitors (TKIs).</p><p><strong>Methods: </strong>We built an economic model to estimate the annual costs of managing ALK+ aNSCLC patients with and without brain metastases using estimated NHS health care resource use (HCRU) consumption. The ALK TKIs included in our model were lorlatinib, crizotinib, alectinib and brigatinib. We based our estimates on the cumulative incidence of brain metastases in four clinical trials - CROWN, ALEX, ALESIA and ALTA-1L.</p><p><strong>Results: </strong>For the first year of treatment, our model estimated the annual cost of managing patients with brain metastases to be £14,870. Patients without brain metastases cost £4,133. The NHS HCRU cost savings generated by treating patients with lorlatinib increased significantly over time and were greater in patients without brain metastases at the start of their treatment (at baseline) with lorlatinib. This reflects the prevention of brain metastases with 1 L lorlatinib.</p><p><strong>Conclusion: </strong>The longitudinal cost data demonstrate that lorlatinib leads to potentially lower NHS management costs of brain metastases in patients with <i>ALK</i>+ aNSCLC.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"15 1","pages":"2696220"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13390505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148550788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncogenic <i>ALK</i> fusion in rare subtype of small intestine metastasis from occult lung cancer.","authors":"Tianhua Liu, Yizhuo Chen, Ziqing Xu, Ming Dong","doi":"10.1080/17581966.2024.2364582","DOIUrl":"10.1080/17581966.2024.2364582","url":null,"abstract":"<p><p>We present the case of a 66-year-old male patient who was found to have a lung nodule during the perioperative period for poorly differentiated carcinoma of the ileocecal region. Subsequent surgical procedures were performed to remove the intestinal and lung masses. Next-generation sequencing (NGS) testing demonstrated that the intestinal and lung lesions exhibited the same <i>ALK</i> pathogenic fusion. Following 7 months of Alectinib treatment, the patient's clinical evaluation showed stable disease. This is the first report of intestinal metastases from lung cancer with <i>ALK</i> fusion. Our findings indicate that a comprehensive approach, including histopathological examination and genetic testing, is necessary to diagnose and treat intestinal metastases from lung cancer accurately.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"14 1","pages":"2364582"},"PeriodicalIF":0.9,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between blood-based <i>HYAL2</i> methylation and early-stage lung cancer: a case-control study.","authors":"Rong Qiao, Xiajie Zhou, Wenli Li, Runbo Zhong, Jun Wang, Yakang Song, Jing Zhang, Tian Xu, Yue Wang, Liping Dai, Wanjian Gu, Baohui Han, Rongxi Yang","doi":"10.1080/17581966.2025.2477411","DOIUrl":"10.1080/17581966.2025.2477411","url":null,"abstract":"<p><strong>Background: </strong>Blood-based DNA methylation biomarkers have great potential for the early detection of lung cancer (LC). Here, we investigated the association between <i>HYAL2</i> methylation in peripheral blood and LC.</p><p><strong>Methods: </strong>Matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass spectrometry was performed to measure the methylation levels of 4 CpG sites in <i>HYAL2</i> gene in two independent case-control studies (168 LC cases and 167 controls in Study I, 677 LC cases and 833 controls in Study II). Logistic regression adjusted for covariates was conducted for odds ratios (ORs) and 95% confidence intervals (CIs). Non-parametric tests were applied for the comparisons of stratified groups.</p><p><strong>Results: </strong>Hypomethylation of all 4 CpG sites in <i>HYAL2</i> was associated with early-stage LC in the two studies (ORs range from 1.91 to 3.07 in Study I, ORs range from 1.39 to 1.86 in Study II, <i>p</i> < 0.05 for all). The associations were still significant for the very early-stage LC patients (stage I). Subgroup analysis indicated that the associations could be enhanced by male gender and older age. Moreover, decreased <i>HYAL2</i> methylation was correlated with increased tumor size, tumor length and stage.</p><p><strong>Conclusions: </strong>Our results suggested blood-based <i>HYAL2</i> hypomethylation as a potential biomarker for LC early detection.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"14 1","pages":"2477411"},"PeriodicalIF":0.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143765047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung cancer screening in limited resource regions: the 3rd Brazilian Early Lung Cancer Trial (BRELT3/mobile ProPulmão).","authors":"Ricardo Sales Dos Santos, Ricardo G Figueiredo, Juliana P Franceschini, Cesar Augusto de Araújo Neto, Almério de Souza Machado Júnior, Bruno Hochhegger, Mario Claudio Ghefter, Ulisses Amancio Pereira Neto, Petrucio Abrantes Sarmento, Igor Barbosa Ribeiro, Daniel Augusto Xavier Carvalho, Felipe S Passos, Caio Santos Holanda, Marcel Samuel Blech Hamaoui, Gustavo Borges da Silva Teles, Carolina Alves Neves, Helena Alves Costa Pereira, Jackline Pereira Leto, Adelmo de Souza Machado Neto, Audrey Cabral Ferreira de Oliveira, Fernando Nunes Galvão de Oliveira, Clarissa Mathias, César Garcia Machado, Josiane Dantas Viana Barbosa, Marine Oliveira Barbosa Santos, Crislaine Gomes da Silva, Mariana Moreira da Silva, Lila Teixeira de Araújo, Álvaro A Cruz","doi":"10.1080/17581966.2025.2513179","DOIUrl":"10.1080/17581966.2025.2513179","url":null,"abstract":"<p><strong>Aims: </strong>To describe tomographic findings in a high-risk lung cancer population in resource-limited Brazilian areas, quantify pulmonary nodules and lung cancer frequency, analyze challenges in lung cancer screening within the Brazilian public health system, assess lung function in individuals with moderate or severe emphysema, and evaluate the role of community health agents in recruiting high-risk populations.</p><p><strong>Methods: </strong>This is a prospective, single-arm, longitudinal observational study involving individuals aged 50-80 years, current or former smokers with a smoking history of at least 20 pack-years, undergoing low-dose computed tomography (LDCT) with a 12-month follow-up. Screening results are classified according to Lung-RADS v2022 standards, with those rated as 3 or 4 undergoing further diagnostic assessments. The study aims to demonstrate the feasibility and effectiveness of lung cancer screening in socially vulnerable populations within resource-limited settings, providing essential insights to reduce mortality and improve health outcomes.</p><p><strong>Conclusions: </strong>The findings will assist the development of policies on lung cancer screening in the public health system. The study's dissemination plan includes a website, social media, and participation in scientific conferences.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"14 1","pages":"2513179"},"PeriodicalIF":0.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144250133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Negative social determinants of health are linked to lung cancer screening underutilization.","authors":"Vuong V Do, Eduardo R Núñez, Fatima G Wilder, Nhung Nguyen","doi":"10.1080/17581966.2025.2583639","DOIUrl":"10.1080/17581966.2025.2583639","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to examine the association between social determinants of health (SDOH) and lung cancer screening (LCS) utilization.</p><p><strong>Methods: </strong>We analyzed data from 15,957 LCS-eligible individuals in the 2022 Behavioral Risk Factor Surveillance System survey. Primary outcomes included ever having (lifetime) LCS and meeting LCS recommendations (i.e., annual LCS). Multivariable logistic regression models examined associations between LCS outcomes and 12 adverse SDOH factors, controlling for covariates (i.e., demographics, diagnosis of asthma/COPD, and perceived general health status).</p><p><strong>Results: </strong>LCS-eligible individuals with more adverse SDOH had lower odds of ever having LCS and being up to date. Those with ≥5 adverse SDOH had the lowest odds of having lifetime LCS (AOR = 0.58, 95%CI: 0.45-0.74) and meeting LCS recommendations (AOR = 0.49, 95%CI: 0.36-0.65) compared to those with none. Life dissatisfaction, lack of social and emotional support, housing insecurity, lack of health insurance, and cost as a barrier for needed medical care were independently associated with lower LCS uptake.</p><p><strong>Conclusions: </strong>Having more adverse SDOH was associated with a lower likelihood of having lifetime LCS and meeting the recommendation, with life dissatisfaction, lack of social and emotional support, housing insecurity, lack of health insurance, and medical care cost being independently associated factors.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"14 1","pages":"2583639"},"PeriodicalIF":0.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12599550/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145453567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction and validation of an oxidative phosphorylation-related gene signature in lung squamous cell carcinoma patients.","authors":"Ninghuang Dai, Chen Fang, Yu Gu, Bin Wang, Wei Feng, Kaifang Pan, Wei Jiang, Guangbin Li, Haitao Ma","doi":"10.1080/17581966.2025.2597179","DOIUrl":"10.1080/17581966.2025.2597179","url":null,"abstract":"<p><strong>Background: </strong>Metabolic reprogramming, particularly toward oxidative phosphorylation (OXPHOS), is a hallmark of lung squamous cell carcinoma (LUSC) and contributes to its aggressive phenotype and immunosuppressive microenvironment. While OXPHOS activation is increasingly recognized as a key metabolic feature in LUSC, its prognostic implications and associated gene signatures remain underexplored. This study aimed to identify OXPHOS-related differentially expressed genes (DEGs) and construct a robust prognostic signature for LUSC.</p><p><strong>Methods: </strong>Using GEO datasets, we developed an OXPHOS-related prognostic signature <i>via</i> ssGSEA, differential analysis, and LASSO-Cox regression.</p><p><strong>Results: </strong>An 8-gene OXPHOS-related signature (LTBP1, MFGE8, ACTN1, CD59, CDC25C, SAAL1, SFXN4, PTTG1) was identified. High-risk patients exhibited significantly shorter overall survival than low-risk patients across all cohorts. The model demonstrated strong predictive accuracy for 1-, 3-, and 5-year survival. Notably, the high-risk group showed enriched pathways related to tumor stemness and immunosuppression.</p><p><strong>Conclusion: </strong>We developed and validated a novel OXPHOS-based gene signature that effectively stratifies LUSC patients by risk. This signature highlights the clinical relevance of OXPHOS in LUSC prognosis and may guide personalized therapeutic strategies targeting metabolic vulnerabilities. Study limitations include its retrospective design and lack of experimental validation.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"14 1","pages":"2597179"},"PeriodicalIF":0.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12688223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145679078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pooled analysis of oral vinorelbine as single agents in patients with advanced NSCLC.","authors":"Christos Chouaid, Francesco Grossi, Christine Ta Thanh Minh, Romain Raymond, Joaquim Bosch-Barrera","doi":"10.1080/17581966.2025.2477418","DOIUrl":"10.1080/17581966.2025.2477418","url":null,"abstract":"<p><strong>Objectives: </strong>This was a pooled analysis of data from weekly vinorelbine (VNR) treatment arms of four individual open-label, phase II studies to assess and refine the efficacy and tolerance of weekly oral VNR in a larger cohort of patients with advanced NSCLC.</p><p><strong>Materials and methods: </strong>All patients included in this pooled analysis received oral VNR at the dose of 60 mg/m² weekly at cycle 1 (3-week cycle), followed by an increase to 80 mg/m² weekly for subsequent cycles until disease progression or toxicity. Efficacy was based on objective response rate (ORR), progression-free survival (PFS), and disease control rate (DCR).</p><p><strong>Results: </strong>A total of 247 patients were included. The ORR and DCR were 8.9% and 57.5% respectively, median PFS and OS were 3.3 and 8.5 months, respectively. Less than half (40.7%) of patients reported ≥1 serious AE (regardless of causality), with 12.3% reporting ≥1 treatment-related serious AE (grade ≥3: 11.1%). The most reported grade ≥3 AEs were neutropenia (17.6%), fatigue (5.8%), and decreased appetite (4.9%).</p><p><strong>Conclusion: </strong>This pooled analysis showed that weekly oral VRN is a valid option, with an acceptable safety profile, in this population of patients with advanced NSCLC, confirming results from previous individual studies.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"14 1","pages":"2477418"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938966/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rucaparib in refractory pleural mesothelioma harboring somatic pathogenic BRCA1 and BRCA2 mutation. A report of two cases.","authors":"Luigi Cerbone, Benedetta Del Rio, Sara Delfanti, Francesco Boccuzzi, Paola Barbieri, Antonina Maria De Angelis, Stefano Meda, Laura Savi, Luisella Righi, Marika Sculco, Irma Dianzani, Paolo Bironzo, Federica Grosso","doi":"10.1080/17581966.2024.2424133","DOIUrl":"10.1080/17581966.2024.2424133","url":null,"abstract":"<p><p>Pleural mesothelioma is a rare disease with few therapeutic options, especially in the first line refractory setting. Targeted agents did not demonstrate a significant clinical benefit in mesothelioma treatment, nevertheless a small group of patients might harbor potentially actionable somatic mutations, as in homologous repair recombination genes. In this paper we report two cases of patients with heavily pretreated pleural mesothelioma that had a relevant clinical benefit with rucaparib treatment based on somatic BRCA 1 and BRCA 2 mutations detected through next generation sequencing.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"14 1","pages":"2424133"},"PeriodicalIF":0.7,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11622792/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145744989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased sympathetic nervous system impairs prognosis in lung cancer patients: a scoping review of clinical studies.","authors":"Fabrício T Garramona, Telma F Cunha, Janaína S Vieira, Gabriela Borges, Gabriela Santos, Gilberto de Castro, Carlos Ugrinowitsch, Patrícia C Brum","doi":"10.2217/lmt-2023-0006","DOIUrl":"10.2217/lmt-2023-0006","url":null,"abstract":"<p><strong>Aim: </strong>To summarize current knowledge, gaps, quality of the evidence and show main results related to the role of the autonomic nervous system in lung cancer.</p><p><strong>Methods: </strong>Studies were identified through electronic databases (PubMed, Scopus, Embase and Cochrane Library) in October 2023, and a descriptive analysis was performed. Twenty-four studies were included, and most were observational.</p><p><strong>Results: </strong>Our data indicated an increased expression of β-2-adrenergic receptors in lung cancer, which was associated with poor prognosis. However, the use of β-blockers as an add-on to standard treatment promoted enhanced overall survival, recurrence-free survival and reduced metastasis occurrence.</p><p><strong>Conclusion: </strong>Although the results herein seem promising, future research using high-quality prospective clinical trials is required to draw directions to guide clinical interventions.</p>","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"12 4","pages":"LMT63"},"PeriodicalIF":0.9,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10794895/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139492429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of combined detection of plasma cfDNA concentration and integrity in NSCLC","authors":"Sai Ren, Chunli Yu, Qing Huang","doi":"10.2217/lmt-2023-0009","DOIUrl":"https://doi.org/10.2217/lmt-2023-0009","url":null,"abstract":"Aim: To evaluate the value of combined detection of plasma cfDNA concentration and integrity in the early diagnosis of NSCLC. Methods: Real-time fluorescence quantitative PCR was used to determine the concentration and integrity of plasma cfDNA in 71 NSCLC patients and 53 healthy people. Results: Combined detection of plasma cfDNA concentration and integrity had higher diagnostic power in differentiating NSCLC patients with stage I/II from healthy people than detection of plasma cfDNA concentration alone or integrity alone. The AUC, sensitivity and specificity of the combined detection of plasma cfDNA concentration and integrity were 0.781, 0.62 and 0.85. Conclusion: Combined detection of plasma cfDNA concentration and integrity could improve the diagnostic value in NSCLC detection.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":"8 9","pages":""},"PeriodicalIF":2.8,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139438171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}